Upon execution of an Implementing Letter in the form attached which specifies the materials to be transferred, this organization agrees to be bound by the terms of the attached Material Transfer Agreement for Genetically Modified Organisms (“MTA”).

Attachments: MTA

Implementing Letter

Organization: Name: Address: Street: Zip code: City:

Country: Authorized Official:

Title:

Name:

Signature: ……………………………………………… Date:

Please sign here

Please return an executed PDF copy of this Master Agreement (e.g. MTA and

Implementing Letter) to the PROVIDER SCIENTIST with cc to: [**MTA@dkfz.de**](mailto:MTA@dkfz.de)

**Material Transfer Agreement for Genetically Modified Organisms (“MTA”)**

I. Definitions:

1. PROVIDER: Organization providing the ORIGINAL MATERIAL. The name and address of this party will be specified in an implementing letter.

2. PROVIDER SCIENTIST: The name and address of this party will be specified in an implementing letter.

3. RECIPIENT: Organization receiving the ORIGINAL MATERIAL. The name and address of this party will be specified in an implementing letter.

4. RECIPIENT SCIENTIST: The name and address of this party will be specified in an implementing letter.

5. ORIGINAL MATERIAL: The description of the material being transferred will be specified in an implementing letter.

6. MATERIAL: ORIGINAL MATERIAL, PROGENY, and UNMODIFIED DERIVATIVES. The MATERIAL shall not include: (a) MODIFICATIONS, or (b) other

substances created by the RECIPIENT through the use of the MATERIAL which are not MODIFICATIONS, PROGENY, or UNMODIFIED DERIVATIVES.

7. PROGENY: Unmodified descendant from the ORIGINAL MATERIAL, such as virus from virus, cell from cell, or organism from organism.

8. UNMODIFIED DERIVATIVES: Substances created by the RECIPIENT which constitute an unmodified functional subunit or product expressed by the ORIGINAL MATERIAL. Some examples include: subclones of unmodified cell lines, purified or fractionated subsets of the ORIGINAL MATERIAL, proteins expressed by DNA/RNA supplied by the PROVIDER, or monoclonal antibodies secreted by a hybridoma cell line.

9. MODIFICATIONS: Substances created by the RECIPIENT which contain/incorporate the MATERIAL.

10. COMMERCIAL PURPOSES: The sale, lease, license, or other transfer of the MATERIAL or MODIFICATIONS to a for-profit organization. COMMERCIAL PURPOSES shall also include uses of the MATERIAL or MODIFICATIONS by any organization, including RECIPIENT, to perform contract research, to screen compound libraries, to produce or manufacture products for general sale, or to conduct research activities that result in any sale, lease, license, or transfer of the MATERIAL or MODIFICATIONS to a for-profit organization. However, industrially sponsored academic research shall not be considered a use of the MATERIAL or MODIFICATIONS for COMMERCIAL PURPOSES per se, unless any of the above conditions of this definition are met.

11. NONPROFIT ORGANIZATION(S): A university or other institution of higher education or any nonprofit scientific or educational organization. As used herein, the term also includes government agencies.

II. Terms and Conditions of this Agreement:

1. The PROVIDER retains ownership of the MATERIAL, including any

MATERIAL contained or incorporated in MODIFICATIONS.

2. The RECIPIENT retains ownership of: (a) MODIFICATIONS (except that, the PROVIDER retains ownership rights to the MATERIAL included therein), and (b) those substances created through the use of the MATERIAL or MODIFICATIONS, but which are not PROGENY, UNMODIFIED DERIVATIVES or MODIFICATIONS (i.e., do not contain the ORIGINAL MATERIAL, PROGENY, UNMODIFIED DERIVATIVES). If either 2 (a) or 2 (b) results from the collaborative efforts of the PROVIDER and the RECIPIENT, joint ownership may be negotiated.

3. The RECIPIENT and the RECIPIENT SCIENTIST agree that the

MATERIAL:

(a) is to be used solely for teaching and academic research purposes exclusively in the field of (optional)

(b) will not be used in human subjects, in clinical trials, or for diagnostic purposes involving human subjects without the written consent of the PROVIDER;

(c) is to be used only at the RECIPIENT organization and only in the RECIPIENT SCIENTIST's laboratory under the direction of the RECIPIENT SCIENTIST or others working under his/her direct supervision; and

(d) will not be transferred to anyone else within the RECIPIENT

organization without the prior written consent of the PROVIDER.

4. The PROVIDER has a non-exclusive license from Cellectis, the exclusive licensee, to Institut Pasteur Patent No. FR 2646438 and corresponding patent applications and patents. If MATERIAL is covered by such patents, RECIPIENT is not allowed to transfer any MATERIAL to third parties.

5. The RECIPIENT and the RECIPIENT SCIENTIST agree to refer to the PROVIDER any request for the MATERIAL from anyone other than those persons working under the RECIPIENT SCIENTIST's direct supervision. To the extent supplies are available, the PROVIDER or the PROVIDER SCIENTIST agrees to make the MATERIAL available, under a separate implementing letter to this Agreement or other agreement having terms consistent with the terms of this Agreement, to other scientists (at least those at NONPROFIT ORGANIZATION(S)) who wish to replicate the RECIPIENT SCIENTIST's research; provided that such other scientists reimburse the PROVIDER for any costs relating to the preparation and distribution of the MATERIAL.

6.

(a) The RECIPIENT and/or the RECIPIENT SCIENTIST shall have the right, without restriction, to distribute substances created by the RECIPIENT through the use of the ORIGINAL MATERIAL only if those substances are not PROGENY, UNMODIFIED DERIVATIVES, or MODIFICATIONS.

(b) Under a separate implementing letter to this Agreement (or an agreement at least as protective of the PROVIDER's rights), the RECIPIENT may distribute MODIFICATIONS to NONPROFIT ORGANIZATION(S) for research and teaching purposes only.

(c) Without written consent from the PROVIDER, the RECIPIENT and/or the RECIPIENT SCIENTIST may NOT provide MODIFICATIONS for COMMERCIAL PURPOSES. It is recognized by the RECIPIENT that such COMMERCIAL PURPOSES may require a commercial license from the PROVIDER and the PROVIDER has no obligation to grant a commercial license to its ownership interest in the MATERIAL incorporated in the MODIFICATIONS. Nothing in this paragraph, however, shall prevent the RECIPIENT from granting commercial licenses under the RECIPIENT's intellectual property rights claiming such MODIFICATIONS, or methods of their manufacture or their use.

7. The RECIPIENT acknowledges that the MATERIAL is or may be the subject of a patent application. Except as provided in this Agreement, no express or implied licenses or other rights are provided to the RECIPIENT under any patents, patent applications, trade secrets or other proprietary rights of the PROVIDER, including any altered forms of the MATERIAL made by the PROVIDER. In particular, no express or implied licenses or other rights are provided to use the MATERIAL, MODIFICATIONS, or any related patents of the PROVIDER for COMMERCIAL PURPOSES.

8. If the RECIPIENT desires to use or license the MATERIAL or MODIFICATIONS for COMMERCIAL PURPOSES, the RECIPIENT agrees, in advance of such use, to negotiate in good faith with the PROVIDER to establish the terms of a commercial license. It is understood by the RECIPIENT that the PROVIDER shall have no obligation to grant such a license to the RECIPIENT, and may grant exclusive or non-exclusive commercial licenses to others, or sell or assign all or part of the rights in the MATERIAL to any third party(ies), subject to any pre- existing rights held by others and obligations to the Federal Government.

9. The RECIPIENT is free to file patent application(s) claiming inventions made by the RECIPIENT through the use of the MATERIAL but agrees to notify the PROVIDER upon filing a patent application claiming MODIFICATIONS or method(s) of manufacture or use(s) of the MATERIAL.

10. Any MATERIAL delivered pursuant to this Agreement is understood to be experimental in nature and may have hazardous properties. The PROVIDER MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE MATERIAL WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS.

11. Except to the extent prohibited by law, the RECIPIENT assumes all liability for damages which may arise from its use, storage or disposal of the MATERIAL. The PROVIDER will not be liable to the RECIPIENT for any loss, claim or demand made by the RECIPIENT, or made against the RECIPIENT by any other party, due to or arising from the use of the MATERIAL by the RECIPIENT, except to the extent permitted by law when caused by the gross negligence or willful misconduct of the PROVIDER.

12. This agreement shall not be interpreted to prevent or delay publication of research findings resulting from the use of the MATERIAL or the MODIFICATIONS. RECIPIENT SCIENTIST shall mention the source of the MATERIAL and the PROVIDER SCIENTIST and responsible PROVIDER members in any publication as co-authors or other appropriate way unless otherwise agreed between PROVIDER SCIENTIST and RECIPIENT SCIENTIST.

13. The RECIPIENT agrees to use the MATERIAL in compliance with all applicaple statutes and regulations, such as, for example, those relating to research involving the use of animals or recombinant DNA.

14. This Agreement will terminate on the earliest of the following dates: (a) when the MATERIAL becomes generally available from third parties, for example, though reagent catalogs or public depositories or (b) on completion of the RECIPIENT's current research with the MATERIAL, or (c) on thirty (30) days written

notice by either party to the other, or (d) on the date specified in an implementing letter, provided that:

(i) if termination should occur under 14(a), the RECIPIENT shall be bound to the PROVIDER by the least restrictive terms applicable to the MATERIAL obtained from the then-available resources; and

(ii) if termination should occur under 14(b) or (d) above, the RECIPIENT will discontinue its use of the MATERIAL and will, upon direction of the PROVIDER, return or destroy any remaining MATERIAL. The RECIPIENT, at its discretion, will also either destroy the MODIFICATIONS or remain bound by the terms of this agreement as they apply to MODIFICATIONS;

and

(iii) in the event the PROVIDER terminates this Agreement under 14(c) other than for breach of this Agreement or for cause such as an imminent health risk or patent infringement, the PROVIDER will defer the effective date of termination for a period of up to one year, upon request from the RECIPIENT, to permit completion of research in progress. Upon the effective date of termination, or if requested, the deferred effective date of termination, RECIPIENT will discontinue its use of the MATERIAL and will, upon direction of the PROVIDER, return or destroy any remaining MATERIAL. The RECIPIENT, at its discretion, will also either destroy the MODIFICATIONS or remain bound by the terms of this agreement as they apply to MODIFICATIONS.

15. Paragraphs 6, 9, and 10 shall survive termination.

16. The MATERIAL is provided at no cost, or with an optional transmittal fee solely to reimburse the PROVIDER for its preparation and distribution costs. If a fee is requested by the PROVIDER, the amount will be indicated in an implementing letter.

**MTA Implementing Letter**

The purpose of this letter is to provide a record of the biological material transfer, to memorialize the agreement between the PROVIDER SCIENTIST (identified below) and the RECIPIENT SCIENTIST (identified below) to abide by all terms and conditions of the MTA, and to certify that the RECIPIENT (identified below) organization has accepted and signed an unmodified copy of the MTA. The RECIPIENT organization’s Authorized Official also will sign this letter if the RECIPIENT SCIENTIST is not authorized to certify on behalf of the RECIPIENT organization. The RECIPIENT SCIENTIST (and the Authorized Official of RECIPIENT, if necessary) should sign this letter and send one signed PDF copy to the PROVIDER SCIENTIST with cc to: [**MTA@dkfz.de.**](mailto:MTA@dkfz.de) The PROVIDER SCIENTIST will forward the material to the RECIPIENT SCIENTIST upon receipt of the signed copy from the RECIPIENT organization.

**A:** (To be filled by the **PROVIDER**)

**PROVIDER:** Organization providing the ORIGINAL MATERIAL Deutsches Krebsforschungszentrum

Im Neuenheimer Feld 280

69120 Heidelberg

Germany

**PROVIDER SCIENTIST:** Name: Prof. M Hollstein

Email: m.hollstein@dkfz.de

Phone: 49-6221-42-33-36

**ORIGINAL MATERIAL:** (Enter description)

5 live male Platform mice for breeding, heterozygous for the Platform Trp53 allele, as described in

Wei et al, Cell Cycle, 2011. The formal „Platform“ mouse strain designation is

B6;129P2(p53)TM182/DKFZ

ORIGINAL MATERIAL is a genetically modified organism classified as biosafety level 1.

Published in:

Wei Q et al., Cell Cycle, 2011

If necessary to restrict the use of the ORIGINAL MATERIAL for specific purposes, please specify permitted exclusive use in the field of (optional):

No restrictions

**B:** (To be filled by the **RECIPIENT**)

**RECIPIENT:** Organization receiving the ORIGINAL MATERIAL

|  |  |  |
| --- | --- | --- |
| Organization: | Name: |  |
| Address: | Street: |
|  | Zip code: | City: |
|  | Country: |  |

**RECIPIENT SCIENTIST:**

Name:

Organization: Name: Address: Street:

Zip code: City: Country:

Email: Phone:

**CONFIRMATION OF COMPLIANCE: Please sign the following:**

RECIPIENT confirms by the signature below that it is authorised and has adequate facilities which comply with all laws and regulations applicable in RECIPIENT’s country to work with ORIGINAL MATERIAL.

Authorized Official of RECIPIENT

(Person authorized to bind RECIPIENT legally by his/her signature)

Name:

Title:

Signature: ………………………………………………

Please sign here

**TRANSMITTAL FEE:** The ORIGINAL MATERIAL is distributed free of charge as a service to the research community. RECIPIENT will bear the shipping costs.

This Implementing Letter is effective when signed by RECIPIENT SCIENTIST and

RECIPIENT. The RECIPIENT SCIENTIST executing this Implementing Letter

certifies that its respective organization has accepted and signed an unmodified copy of this MTA, and further agrees to be bound by its terms, for the transfer specified above.

Signatures intentionally on next page

RECIPIENT SCIENTIST

Name:

Signature: …………………………………………………….. RECIPIENT CERTIFICATION

Certification: I hereby certify that the RECIPIENT has accepted and signed an unmodified copy of this MTA (May be the RECIPIENT SCIENTIST if authorized by the RECIPIENT):

Authorized Official of RECIPIENT

(Person authorized to bind RECIPIENT legally by his/her signature)

Name: Title:

Signature: ……………………………………………………..

Date: ................................................

Please sign here

Please sign here